The Effect of cdna on Tumor Cells Growth on Nude Mice

Similar documents
supplementary information

Genetics - Problem Drill 19: Dissection of Gene Function: Mutational Analysis of Model Organisms

3.1.4 DNA Microarray Technology

Genetics Lecture 21 Recombinant DNA

Gaussia Luciferase-a Novel Bioluminescent Reporter for Tracking Stem Cells Survival, Proliferation and Differentiation in Vivo

Supplementary Figure 1. Characterization of EVs (a) Phase-contrast electron microscopy was used to visualize resuspended EV pellets.

Introducing new DNA into the genome requires cloning the donor sequence, delivery of the cloned DNA into the cell, and integration into the genome.

Green Fluorescent Protein (GFP) Purification. Hydrophobic Interaction Chromatography

7 Gene Isolation and Analysis of Multiple

SureSilencing sirna Array Technology Overview

Supplementary Fig. 1 related to Fig. 1 Clinical relevance of lncrna candidate

Multiple choice questions (numbers in brackets indicate the number of correct answers)

DNA Technology. B. Using Bacteria to Clone Genes: Overview:

Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research.

2054, Chap. 14, page 1

Bio11 Announcements. Ch 21: DNA Biology and Technology. DNA Functions. DNA and RNA Structure. How do DNA and RNA differ? What are genes?

MICB688L/MOCB639 Advanced Cell Biology Exam II

HISTORY AND BACKGROUND

64 CuCl 2 in 50 µl 0.1N NaOAc buffer, and 20 µg of each DOTA-antibody conjugate in 40 µl

Supporting Information: Core-Shell Nanoparticle-Based Peptide Therapeutics and Combined. Hyperthermia for Enhanced Cancer Cell Apoptosis

Tumor Growth Suppression Through the Activation of p21, a Cyclin-Dependent Kinase Inhibitor

Supporting Online Material for

Thermo Scientific DharmaFECT Transfection Reagents sirna Transfection Protocol

M Keramatipour 2. M Keramatipour 1. M Keramatipour 4. M Keramatipour 3. M Keramatipour 5. M Keramatipour

Supplemental Table 1 Gene Symbol FDR corrected p-value PLOD1 CSRP2 PFKP ADFP ADM C10orf10 GPI LOX PLEKHA2 WIPF1

Bio 101 Sample questions: Chapter 10

Topical sirna for management of androgenic alopecia and oily skin Quark Pharmaceuticals, Inc.

Supplemental Data. LMO4 Controls the Balance between Excitatory. and Inhibitory Spinal V2 Interneurons

Recombinant DNA Technology

A Level. A Level Biology. DNA Technology Questions. AQA, OCR, Edexcel. Name: Total Marks: Page 1

DNA Transcription. Visualizing Transcription. The Transcription Process

mir-24-mediated down-regulation of H2AX suppresses DNA repair

thebiotutor.com 5C Genetic Modification Time: 34 minutes Total marks available: 34 Total marks achieved: Andy Todd

Convoy TM Transfection Reagent

Gene Expression Technology

Functional characterisation

LECTURE 5: LINKAGE AND GENETIC MAPPING

Use of Gene Editing Technologies in Rodents. Carlisle P. Landel, Ph.D.

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE

Data Sheet. Hippo Pathway TEAD Reporter MCF7 Cell Line Catalog #: 60618

The Comet Assay How to recognise Good Data

Biology 252 Nucleic Acid Methods

Chapter 14: Genes in Action

TransIT -BrCa Transfection Reagent

PV92 PCR Bio Informatics

Concepts: What are RFLPs and how do they act like genetic marker loci?

Computational Biology I LSM5191

Lecture Four. Molecular Approaches I: Nucleic Acids

Exam MOL3007 Functional Genomics

BEST PRACTICES IN MOUSE TISSUE SAMPLE PREPARATION FOR RNA EXTRACTION WITH PRECELLYS EVOLUTION

Friedrich Miescher (1869) Isolated nucleic acids from the nuclei of white blood cells

PrimePCR Assay Validation Report

EECS730: Introduction to Bioinformatics

Nanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management

SECTION I CITIZENSHIP: CITIZENSHIP: SECTION II

Cat # Box1 Box2. DH5a Competent E. coli cells CCK-20 (20 rxns) 40 µl 40 µl 50 µl x 20 tubes. Choo-Choo Cloning TM Enzyme Mix

Introduction to C. elegans and RNA interference

Chapter 8 Cell Diversity

IBC protocol Risk Assessment and Determination of NIH Guidelines

Antibody Structure. Antibodies

Antibody Structure supports Function

Updates to the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)

DNA Structure and Analysis. Chapter 4: Background

Higher Human Biology Unit 1: Human Cells Pupils Learning Outcomes

The Polymerase Chain Reaction. Chapter 6: Background

Learning Objectives :

How Do You Clone a Gene?

Make the protein through the genetic dogma process.

INTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS. Guy Cavet

BIOTECHNOLOGY OLD BIOTECHNOLOGY (TRADITIONAL BIOTECHNOLOGY) MODERN BIOTECHNOLOGY RECOMBINANT DNA TECHNOLOGY.

Synthetic Biology for

Figure S1. Figure S2. Figure S3 HB Anti-FSP27 (COOH-terminal peptide) Ab. Anti-GST-FSP27(45-127) Ab.

Genetic material must be able to:

Bio 121 Practice Exam 3

HighPrep Blood & Tissue DNA Kit

PrimePCR Assay Validation Report

Embryonic development, epigenics and somatic cell nuclear transfer - The science and its social implications -

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University

Name Class Date. Practice Test

Human IL-10 ELISA MAX Set Deluxe

TRANSGENIC TECHNOLOGIES: Gene-targeting

We are committed to translating ground-breaking science into genomic therapies that transform patients lives

Genome Sequence Assembly

REGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH

CHAPTER 20 DNA TECHNOLOGY AND GENOMICS. Section A: DNA Cloning

Custom Antibodies Services. GeneCust Europe. GeneCust Europe

Recombinant DNA Technology. The Role of Recombinant DNA Technology in Biotechnology. yeast. Biotechnology. Recombinant DNA technology.

Genetic Engineering & Recombinant DNA

Adding CRISPR to Your Bio-ARROW Protocol

DEPArray Technology. Sorting and Recovery of Rare Cells

Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL

CELLTECHGEN For Research Only. Construction of all-in-one vector for Lenti-virus system (Example: Lenti-EF1 -Cas9-EGFP-U6 sgrna vector)

Pre-lab Homework Lab 1: Issues in Genetics

INTRODUCTION TO REVERSE TRANSCRIPTION PCR (RT-PCR) ABCF 2016 BecA-ILRI Hub, Nairobi 21 st September 2016 Roger Pelle Principal Scientist

Lecture 25 (11/15/17)

CHAPTER 21 LECTURE SLIDES

Themes: RNA and RNA Processing. Messenger RNA (mrna) What is a gene? RNA is very versatile! RNA-RNA interactions are very important!

Bio-Reagent Services. Custom Gene Services. Gateway to Smooth Molecular Biology! Your Innovation Partner in Drug Discovery!

Transcription:

The Effect of cdna on Tumor Cells Growth on Nude Mice Yiming Ding Department of Electric and Computer Engineering Portland State University, OR Email: dym@cecs.pdx.edu This project is assigned in the class Learning from Data, offered in Winter 2002. 1

Abstract: CSK homologous kinase (CHK) is a negative growth regulator of human breast cancer. This study shows that the recombinant DNA of CHK affects breast cancer growth and DNA of CHK and DNA of CSK affect ovarian cancer growth on nude mice. The data are processed statistically and demonstrate the cdnas posses inhibitory effect on tumor growth. cdna is strong, cloned copies of otherwise fragile mrna - the essential messenger element of the genes in the DNA which help in the coding of proteins. Recombinant DNA refers to DNA, which has been altered by joining genetic material from two different sources. It usually involves putting a gene from one organism into the genome of a different organism, generally of a different species. Keywords: CHK, nude mice and cancer. Introduction CSK homologous kinase (CHK) is a novel negative growth regulator of human breast cancer. In previous studies, it is well known that the CHK(DNA) possess inhibitory effect on breast cancer cells growth in vivo as well as in vitro studies. Also it is known that recombination DNA CHK shows the same effect in vitro studies. Figure 1 shows the in vivo study of CHK effect on the breast cancer MCF-7 cells. Four subtype MCF-7 cells were injected into nude mice with same amount. Type one: wild-type MCF-7 cells. Type two: MCF-7 cells transfected with pcdna-iii(vector). Type three: MCF-7 cells transfected with mutant CHK gene. Type four: MCF-7 cells transfected with CHK gene We could see that the tumors with CHK gene disappeared after 45 days and it was confirmed by dissection. The tumors with mutant CHK gene were much smaller than tumors of wild type MCF-7 and tumors with vector alone. 2

MCF-7 Cells Growth Curve on Nude Mice 250 Volume (cubit mm) 200 150 100 50 0 day 10 day15 day 23 day 31 day 37 day 45 day 52 Day wild type vector CHK mt CHK Fig. 1 CHK effects on MCF-7 cells growth in vivo. Two experiments were performed in Dr. Hava Avraham s Lab, Department of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston. The purpose was to observe the tumor growth on nude mice in the conditions of cdna, Chitosan(a compound protecting DNA from digestion of DNAse in the blood), or combinations injected into mice. We try to answer the question: Do the cdnas have an inhibitory effect on tumor growth in vivo? in our research. Methodology Animal model: 3 week-5 week old female nude mice were injected with pre-cultured breast cancer cells, under the skin of lower abdomen, 6 5 10 cells per each mouse. The cells were resuspended in 300 µ l Phosphate Buffer Saline and Matrigel with ratio of 1:1. In the 3

first experiment breast cancer MDA-MB-231 cells were injected to the mice while the second experiment ovarian cancer SK-OV-3 cells were injected. Grouping: Randomly group the mice into 4 to 6 groups, 4 to 5 mice for each group (basically the number of mice in each group is equal in each experiment). Measurement: After 7-10 days injection of tumor cells, the injection sites became solid, we measured the sizes of the masses in three dimensions (length, width and depth), and followed up to the end of the experiment (at least three weeks). Measurements were taken twice a week. DNA and Chitosan preparation: 500 µ g DNA were dissolved in 200 µ l 500mM Sulfate Sodium. Chitossan were dissolved in Sulfate Sodium with 0.2% concentration. Treatment: When the tumor becomes solid, we started injection of same dose (100 µ g ) cdnas, Chitosan or combinations twice a week, except the control group. In the first experiment, we injected Chitosan, Chitosan plus pcdnaiii(vector), Chitosan plus CHK or Chitosan plus mutant CHK. In the second experiment, we injected Chitosan, Chitosan plus CHK, Chitosan plus mutant CHK, Chitosan plus CSK or Chitosan plus mutant CSK. We also gave injection of phosphate buffer saline to the mice in the control group. Experiment results: In the first experiment, after half month of the treatment, the volume of tumors in the control group was much larger than that in other groups(fig. 2). In the second experiment, after three weeks of treatment there were some differences in volume of tumors between the groups(fig. 3). 4

Exp. 1: cdna Effects on MDA-MB-231 Tumor Growth on Nude Mice Volume(Cubic mm) 400 350 300 250 200 150 100 50 0 Day 3 Day 6 Day 10 Day 13 Day 17 Day 20 Day 24 control Chitosan pcdna3+chitosan CHK+Chitosan CHK(mt)+Chitosan Fig. 2 Experiment 1:cDNA s Effects on MDA-NA-231 Cells growth Exp2 cdna Treatment Effects on SK-OC-3 Cells Growth on Nude Mice Volume(Cubic mm) 1000 900 800 700 600 500 400 300 200 100 0 DAY 23 DAY 29 DAY 37 DAY 44 PBS Chitosan CHK+Chitosan CHK(mt)+Chitosan CSK+Chitosan CSK(mt)+Chitosan Fig. 3 Experiment 2:cDNA s Effects on SK-OC-3 Cells growth Statistic Analysis and Discussion 5

Due to the purpose of the study, the interested parameter was Growth Rate of Tumor, Y2 Y1 defined as the increasing volume of mass in certain period ( Rate = ). X X Y1: Volume at the beginning Y2: Volume at the end X1: Starting time (day) X2: Ending time (day) The first step is to calculate the growth rate of tumors from raw data in each experiment. Table 1 and table 2 show the results. Animal ID Growth rate Control 1 32.29 2 12.14 3 12.29 4 6.76 5 7.52 Chitosan 1 6.76 2 7.81 3 0 4 2.57 5-1.33 Chitosan+Vector 1-1.62 2 0.33 3 5.71 CHK+Chitosan 1 1.9 2 1.29 3 6.29 4 6 5 0.71 CHK(mt)+Chitosan 1 1.24 2 1.57 3 1.05 4 5.05 5 5 Table 1. Growth rates of tumors in experiment 1 2 1 6

Animal ID Growth rate Control 1 53.14 2 56.29 3 12 4 33.29 Chitosan 1 26.29 2 41.14 3 14.29 4 11.67 CHK+Chitosan 1 3.62 2 5.81 3 17.19 4 14.10 CHK(mt)+Chitosan 1 10.29 2 6.86 3 24.29 4 5.48 CSK+Chitosan 1 3.14 2 10.86 3 13.71 4 9.52 CSK(mt)+Chitosan 1 14.14 2 7.62 3 6.14 4 17.24 Table 2. Growth rates of tumors in experiment 2 The second step is to test the data with lilletest, the histograms show that the growth rates are not normal distributed (fig.4 and fig.5). The third step is to compare the growth rate between control group and other groups by pair using Rank-Sum Test (Non- parametric method). This method does not require large number of samples in each group. There were two hypothesis: H0: The growth rate of the tumor in control group(µ 1 ) is equal to the rate in cdna groups(µ 2 ) at 0.05 significant level. 7

8-5 0 5 10 15 20 25 30 35 0 1 2 3 4 5 6 7 8 9 Fig. 4 Growth rate distribution in experiment 1 0 10 20 30 40 50 60 0 1 2 3 4 5 6 Fig. 5 Growth rate distribution in experiment 2

H1: The growth rate of the tumor in control group (µ 1 ) is greater than the rate in cdna groups(µ 2 ) at 0.05 significant level. Table 3 shows the way of Rank-Sum Test To Test H 0 Versus H 1 Compute µ 1 = µ 2 µ 1 < µ 2 µ 1 > µ 2 µ 1 µ 2 µ 1 µ 2 µ Table 3.Rank-Sum Test Decision criteria of Rank-Sum test: If the observed value µ, µ1, or µ2 is less than or equal to the table critical value, we reject H0. This report computed µ 2 and chose one tailed at 0.05 significant level. Table 4 and table 5 show the outcomes of the Rank-Sum test of the two experiments. µ 2 Critical Value Control/Chitosan 2.5 4 Control/Chitosan+Vector 0 4 Control/CHK+Chitosan 0 4 Control/CHK(mt)+Chitosan 0 4 Table 4. Rank-Sum test outcome of experiment 1 µ 2 Critical Value Control/Chitosan 4 1 Control/CHK+Chitosan 2 1 Control/CHK(mt)+Chitosan 1 1 Control/CSK+Chitosan 1 1 Control/CSK(mt)+Chitosan 2 1 Table 5. Rank-Sum test outcome of experiment 2 In the first experiment, the result of Rank-Sum test rejects H 0 in all comparison pairs. In the second experiment, the result of Rank-Sum test rejects H 0 in comparison pairs of Control 9

versus mutant CHK plus Chitosan and Control versus CSK plus Chitosan; but fails to reject H 0 in other comparison pairs. Conclusion Based on the statistic analysis on the experiments, we can conclude: 1. Both CHK and mutant CHK can inhibit MDA-MB-231 cells growth on nude mice. 2. CHK and mutant CSK do not inhibit SK-OV-3 cells growth on nude mice, but CSK and mutant CHK do. Acknowledgement Thank Dr. Hava Avraham s support and Yigong Fu s contribution to this project. Thank Dr. James McName s for his guides to the statistics analysis 10